Physician profile
Solomia Pullen
NPI 1346916327
$3,205.02
in general payments reported to CMS, 2019-2025
17 companies · $1,238 in 2025
The $1,238 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $255 · 2023: $1,311 · 2024: $401 · 2025: $1,238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,833 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,832.73 |
| Education | $117.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $722.05 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $683.82 | 2022-2025 | Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $446.50 | 2022-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $368.88 | 2023-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $294.81 | 2023-2025 | |
| Genentech USA, INC. | $133.07 | 2023-2025 | Xolair |
| Sanofi-Aventis U.S. LLC | $99.99 | 2025 | |
| Optinose US, INC. | $77.99 | 2023-2025 | |
| Grifols USA, LLC | $60.41 | 2024-2025 | Xembify |
| Biocryst US Sales Co., LLC | $57.70 | 2025 | Orladeyo |
| Ars Pharmaceuticals Operations, INC. | $56.44 | 2025 | Neffy |
| Csl Behring | $44.28 | 2025 | Hizentra, Andembry |
| Amgen INC. | $41.20 | 2023-2024 | Tezspire |
| Kaleo, INC. | $37.36 | 2022-2023 | Auvi-Q |
| Alk-Abello, INC | $37.22 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $25.26 | 2022 | |
| Pfizer INC. | $18.04 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Solomia Pullen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.